

1. [Sun Pharma: Adjusting to the new reality](#) – Mint

The company's March quarter numbers were quite good. It has been selling its generic version of cancer drug Gleevec in the US market since February, and will be the sole generic product for six months. One could be, if the Halol facility inspection gets clearance from the US Food and Drug Administration earlier than expected, and improved supplies lead to better sales growth. A more stable foreign currency environment in developing markets can be another positive factor. Positive news flows on its research programmes is yet another factor.

1. [Sun Pharma: Adjusting to the new reality](#) – Mint
2. ['India a giant importer of energy, food, manufactured products'](#) – Times of India
3. [Boehringer Ingelheim](#) – Times of India
4. [Nagpur oral cancer capital of the world](#) – Times of India
5. [3000 to gain as PM okays move to retire govt doctors at 65](#) – Times of India
6. [Experts discuss new Intellectual Property Rights Policy](#) – The Hindu
7. [National IPR Policy - Pharmabiz](#)
8. [Plastic bottles contaminate medicines, shows study](#) – The Wire

2. ['India a giant importer of energy, food, manufactured products'](#) – Times of India

Consul General of Indonesia Saut Siringoringo expressed optimism that bilateral trade between India and Indonesia could expand to sectors like IT, education, health, pharma, auto and auto parts, finance and textiles. The main items of India's exports to Indonesia include petroleum products, telecommunication equipment and parts, hydrocarbons and derivatives, oil seed, motor vehicle for goods transportation, animal feed, cotton and alloy steel. India's imports from Indonesia include fixed vegetable fats and oil, coal, copper ores, natural rubber, pulp and waste paper, alcohol and phenols, medicinal and pharmaceutical products, fertilizers among others.

3. [Boehringer Ingelheim](#) – Times of India

Boehringer Ingelheim and Inventiva, a French biopharmaceutical company specialised in the development of innovative therapies for fibrosis, oncology and orphan diseases, announced today, a new multi-year research and drug discovery collaboration and licensing agreement. Under the terms of the agreement, the Inventiva and Boehringer Ingelheim research teams will jointly validate a new therapeutic concept with the aim of discovering new medicines for the treatment of Idiopathic Pulmonary Fibrosis (IPF) and other fibrotic diseases.

4. [Nagpur oral cancer capital of the world](#) – Times of India

It may appear unbelievable that 50% of cancers in men and 20% in women can directly be attributed to tobacco use. These scary figures come from a study conducted by the Indian Council of Medical Research (ICMR). Over 10 lakh deaths occur due to tobacco in India annually and of these 1 lakh are in Maharashtra alone. The state, however, ranks third in the country in early deaths caused due to tobacco consumption. "Most frightening fact is that every year about 4 lakh new cases are added in Central India alone. Nagpur is regarded as the oral cancer capital of not just India but world due to maximum patients reported here. Hence our hospital, which draws patients from entire Central India, has to proactively work for prevention," he said.

5. [3000 to gain as PM okays move to retire govt doctors at 65](#) – Times of India

Prime Minister Narendra Modi on Tuesday approved the proposal to raise the retirement age of doctors of central health services to 65 years. The move, aimed at addressing the huge shortage

of doctors across the country, will allow experienced doctors to serve for a longer period in public health facilities. PM Modi had made the announcement at a rally in UPs' Saharanpur last week saying there is a need for more doctors across the country but it was not possible to fill the gap in two years of his governance.

6. [Experts discuss new Intellectual Property Rights Policy](#) – The Hindu

With the Centre giving the nod for the national Intellectual Property Rights (IPR) policy, SJCE-STEP in association with MSME-CII-Intellectual Property Facilitation Centre and VTPC-Government Karnataka, organised an interactive session on 'New National IPR Policy: Way Forward' on Tuesday. The interactive session was a platform to understand the objectives, to critically examine the policy and its effect on innovation, R&D in India, and also various sectors of the industry, and the hurdles in implementing the policy. The speakers included: B.G. Sangameshwara, I/c Director (P&D) and chief executive, SJCE-STEP, JSS Technical Institutions Campus; Prabhavathi Rao, program coordinator, WTO and IPR Relay Cell, Visvesvaraya Trade Promotion Centre; Bheemesh M.N., senior advisor, ALMT Legal; Brinda Varma, founding partner, Aekam Legal Abode; Ankita Thacker, senior associate, K&S Partners; Rakesh Babu K.L., director, Innomantra Pvt. Ltd., Mysuru, and K.S. Sudheer, associate solicitor, Shankar and Shankar, Legal Consultants, Mysuru.

7. [National IPR Policy - Pharmabiz](#)

An Editorial piece on the Union Cabinet approved the National Intellectual Property Rights (IPR) Policy by PA Francis. The Editorial talks how the Policy provided some key provisions relating to patentability of a product and opportunities for pre grant and post grant opposition to the affected companies. There is also a provision for grant of compulsory license in case of a national emergency or in the event of non working of the patent for 3 years from the date of grant. Francis, in the editorial, opines that it will be prudent to involve public and private sector institutions and other stakeholders including state governments for its effective implementation. He also points, that delay in deciding the grant of patent by the different patent office's because of inadequate number of examiners has been another key issue.

8. [Plastic bottles contaminate medicines, shows study](#) – The Wire

Contradicting what the health ministry said in March, the Drugs Technical Advisory Board now recommends banning plastic bottles for medicines. Plastic or PET (polyethylene terephthalate) bottles contaminate the medicines stored in them, concluded laboratory tests ordered by the health ministry and endorsed by the country's top statutory authority on standards for medicines, the Drugs Technical Advisory Board (DTAB). Based on the result of the lab tests, the board has recommended banning the bottling of medicines in plastics and PET meant for vulnerable groups, such as children and pregnant women